| Literature DB >> 24442426 |
You-Bing Zheng1, Qing-Wen Meng, Wei Zhao, Bing Liu, Jian-Wen Huang, Xu He, Yong Li, Bao-Shan Hu, Li-Gong Lu.
Abstract
We aimed to elucidate whether serum VEGFR2 concentration before and after transarterial chemoembolization (TACE) can predict survival in patients with unresectable hepatocellular carcinoma (HCC). Serum VEGFR2 concentrations were serially measured in 169 patients with advanced HCC before and after TACE. We defined a decrease in the serum VEGFR2 level>10% from the pretreatment level as response. Serum VEGFR2 concentrations decreased in 44 (26.0%) patients at week 4. Patients who had a VEGFR2 response at week 4 had a longer median survival than those who did not have a VEGFR2 decrease (19.0 vs. 9.8 months, p<0.001). Clinical variables associated with OS in addition to VEGFR2 response also included extrahepatic metastases (p=0.005) and vascular invasion (p=0.035). VEGFR2 decrease after TACE (p=0.012) and presence of extrahepatic metastases (p=0.02) were independently associated with OS by multivariate analysis. A serum VEGFR2 concentration decrease at 4 weeks after TACE may predict favorable overall survival in patients with advanced HCC.Entities:
Mesh：
Substances：
Year: 2014 PMID： 24442426 DOI： 10.1007/s12032-014-0843-5
Source DB: PubMed Journal: Med Oncol ISSN： 1357-0560 Impact factor: 3.064